Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy

Journal of Cardiovascular Magnetic Resonance

Research

David M. Kaye¹  Kyi T. H. Win²  Karen S. Teo³  Daniel J. Scherer³  Prashanthan Sanders⁴  Fiona Thoi⁵  Michael B. Stokes⁶ 

[1] Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia;Department of Clinical Research, The Baker Heart and Diabetes Institute, Melbourne, Australia;Department of Cardiology, The Alfred Hospital, Melbourne, Australia;Department of Medicine, Monash University, Clayton, VIC, Australia;Department of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia;Department of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia;Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;Department of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia;Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia;School of Medicine, University of Adelaide, Adelaide, Australia;School of Medicine, University of Adelaide, Adelaide, Australia;Department of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia;Heart Health Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia;

关键词: Dilated cardiomyopathy;    Heart failure;    Imaging;    Methamphetamine;   

DOI  :  10.1186/s12968-022-00898-6

 received in 2022-05-04, accepted in 2022-10-19,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundMethamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP.MethodsA retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner.ResultsThe mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV).ConclusionMA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq236.gif

12982_2022_119_Article_IEq232.gif

12888_2022_4365_Article_IEq7.gif

12888_2022_4365_Article_IEq5.gif

12888_2022_4365_Article_IEq4.gif